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Introduction
The mammalian PIKK family of proteins is comprised of FRAP, ATM, ATR/FRP, and DNA-PKcs, all of which contain a C-terminal kinase domain related to the phoshoinositide kinase domain 5 . However, the PIKK members are protein kinases, and contain a short segment at their extreme C-terminus not present in the PI3 and PI4 kinases. This C-terminal region is required for kinase activity and is not interchangeable within the family 6 . While the ATM, ATR/FRP, and DNA-PKcs proteins all respond to DNA damage in the cell, FRAP functions to regulate the rate of protein translation in response to mitogenic signals, allowing progression from the G 1 to the S phase of the cell cycle 7 .
FRAP kinase activity promotes the translation of a subset of cellular mRNAs by phosphorylating its targets, p70 s6k (S6K1 and S6K2) and 4E-BP1 and 4E-BP2. The phosphorylation of p70 s6k promotes the phosphorylation of the s6 ribosomal subunit, leading to an increase in translation 8 . FRAP kinase activity also phosphorylates the translation inhibitors 4E-BP1 and 4E-BP2, causing these proteins to dissociate from the translation initiation factor eIF4e, promoting translation 5, 9 . One class of mRNA targets translated by the FRAP signaling pathway is the 5'TOP messages, which contain a 5' terminal oligopyramidine tract 10 . Additionally, FRAP activity increases the translation of mRNAs such as cmyc and cyclin D1 11 . The translation of these classes of mRNAs has been demonstrated to be blocked by rapamycin treatment, a potent inhibitor of FRAP activity [10] [11] .
FRAP has been proposed to be a regulator of cell growth 12 . In yeast, the FRAP homologs TOR1
and TOR2 are thought to act as nutrient sensors and promote translation initiation and cell cycle progression 13 . In Drosophila both the ds6k mutant and FRAP mutants demonstrate reduced cell size [14] [15] [16] . Targeted deletion of the mouse S6K1 gene produces small mice as well, although the presence of a second s6kinase gene in mice (S6K2) may compensate for some S6K1 functions and mask a more severe phenotype 17 . Additionally, the FRAP pathway has been implicated in the growth of mammalian tumors, and rapamycin is being investigated as an anti-tumor drug 18 .
Although several roles of the FRAP signaling pathway have been identified, the function of FRAP in a mouse model has not been determined. Here we present the identification of an ENU induced mutation in the mouse FRAP gene, which illustrates a critical requirement for FRAP in embryonic development. We demonstrate that the FRAP signaling pathway is affected in these mutants.
Additionally, we show that cells in the mouse mutant are not reduced in cell size, unlike the Drosophila FRAP or dS6K mutants, or mouse S6K1 knock-out. Finally, we also determine that rapamycin treatment of mouse embryos produces a phenocopy of the FRAP mouse mutant, indicating that rapamycin is a teratogen.
Methods:

Physical mapping
Overlapping oligonucleotides were used to generate probes from unique sequences surrounding D4MIT206, D4MIT310 and D4 MIT129. These probes were used to screen the mouse RPCI-21 genomic BAC library (http://www.chori.org/bacpac). End sequence from these clones was used to generate PCR primers to determine the order of clones as well as to perform a BLAST search to locate genes in the flat-top interval.
Mutation Analysis
RT-PCR was performed on flat-top mutant, heterozygote and wild-type samples using FRAP primers that amplify across the exon7/ exon 8 junction. The products were radioactively labeled and analyzed on a standard 6% acrylamide sequencing gel. A histogram analysis of the products was performed using a Molecular Dynamics 'Storm' phospho-imager and analyzed using the NIH Image software. The presence of intron 7 sequences in products A and B was confirmed by sequencing.
Rapamycin injections
Wild-type, pregnant C57BL/6J females were treated with three daily doses of 3mg/kg of rapamycin (Calbiochem) starting at 5.5 days post-coitum. A stock solution of 1 mg/ml rapamycin dissolved in methanol was diluted into 500 µl Ringer's Saline immediately before intraperitoneal injection. Control animals treated with carrier alone produced embryos indistinguishable from untreated wild-type.
Enzyme assays:
Western blots were performed as described in reference 19. Blots were probed with anti-p70 (Santa Cruz, cat. #SC-230) or anti-phospho-thr 389 p70 (NEB, cat # 9205s). Approximately 40 flat-top or wild-type embryos were resuspended in lysis buffer. Lysates were incubated with protein G agarose, cleared, and the supernatants were incubated with anti-FRAP or anti-p70 s6k and fresh protein-G agarose.
The samples were then washed as described in reference 16. For the FRAP assay, p70 s6k produced in E.
coli was used as the substrate. After the kinase reaction the samples were analyzed on an 8% SDS acrylamide gel.
For the p70 s6k assay, a peptide derived from the amino acid sequence of S6 ribosomal protein was used as the substrate. After the kinase reaction the samples were transferred to phospho-sepharose squares, washed, and the amount of label incorporated was determined with a scintillation counter.
4E-BP1 Phosphorylation Assay:
Plasmids and antibodies. pcDNA3-flag-FRAP wild-type, kinase dead (Asp2357Glu) and rapamycin resistant (Ser2035Thr) constructs were kindly provided by Dr. Jie Chen (Department of Cell and Structural Biology, University of Illinois, Urbana-Champaign), and were described previously 20 . Flattop insertion and deletion mutants were generated by PCR mutagenesis and cloned into the background of the rapamycin resistant flag-FRAP (Ser2035Thr) construct. The 4E-BP1 plasmid used for transfection
Hentges et al (pACTAG-2-4E-BP1) was described previously 21 . Anti-HA and anti-flag monoclonal antibodies were purchased from BAbCO (Berkeley, CA) and Sigma (St Louis, MO), respectively. The phosphospecific anti-Ser65 and anti-Thr70 antibodies were provided by Cell Signaling Technologies (Beverly, MA).
Expression and purification of a bacterially expressed glutathione-S-transferase (GST) 4E-BP1 fusion protein (pGEX-6P1-4E-BP1 wt) was described previously Flat-top or wild-type embryos at 9.5 dpc were dissected in PBS, 1mM EDTA. Embryos were incubated on ice for 45 minutes, the mid-thoracic region was dissected and incubated in DMEM and a single cell suspension was prepared by trituration. Only mesenchymal cells were liberated by this gentle preparation method and the ectoderm, neuroectoderm and endoderm remained largely intact. Digital images of the cells were captured using DIC microscopy and cell size was measured using NIH Image. The single cell suspension prepared in this way consisted almost exclusively of spherical cells so the cell diameter measurement provides a consistent measure of cell volume.
In situ hybridization A FRAP in situ probe was generated from an RT-PCR product cloned into the TA cloning kit vector (Invitrogen). Primer sequences for RT-PCR are available upon request. In situ hybridizations were carried out as described in reference 22.
Results
The mouse flat-top mutant was isolated in an ENU screen designed to identify recessive forebrain defects 22 . The mutants specifically lack the telencephalon, the anterior-most region of the forebrain.
The flat-top phenotype has been described in detail 22 , and includes a failure to up-regulate cell proliferation in the telencephalon and an inability to maintain gene expression in the pre-chordal region of the forebrain neurectoderm. Mutants also fail to rotate around the embryonic body axis and die at 12.5dpc, at mid-gestation.
To identify the genetic basis of the developmental defects in the flat-top embryo we mapped the mutation to high resolution. Approximately 3000 meiotic events showed complete linkage of the flattop locus with the marker D4MIT310, located between the markers D4MIT206 and D4MIT129, in a region that is homologous to human chromosome 1p35-36. More detailed mapping of the region was carried out by constructing a clone based physical map or contig across the flat-top region ( Fig 1A) .
Both BAC and PAC libraries were screened to identify clones containing D4MIT206, 310 and 129.
End sequences from these clones were then used to screen the same libraries until complete clone coverage of the region was obtained. We generated end sequence from BAC clones in the region and used BLAST searches of the nucleotide databases to align the flat-top region at very high resolution with human genomic sequence of the homologous interval.
Among the genes identified by these approaches was FRAP (also known as mTOR and RAFT1).
To determine whether flat-top mice carried a mutation in the FRAP gene we generated overlapping RT-PCR products covering the entire coding sequence of ~8 kb which were sequenced in their entirety.
One of the primer sets generated two products from homozygous mutant embryo RNA and a single band from wild-type RNA (Fig 1B) . Sequence analysis showed that both PCR products from the flattop embryos contained inserts relative to the wild-type product. Comparison of the cDNA sequence to the human genomic sequence indicated that the inserts corresponded to the location of an intron in the human genomic locus. Sequencing of both wild-type and mutant mouse genomic DNA corresponding to this intron revealed the existence of a single base change within the intron (Fig 1C) . The effects of the mutation on the splicing of the mRNA were examined by carrying out quantitative RT-PCR using primers that spanned this intron. This analysis revealed the existence of two additional, but relatively rare, forms of mRNA in mutant embryos in contrast to the single form present in wild-type embryos (Shown schematically in Fig 1C) . mRNA produced by a normal splice event comprised about 5% of the total FRAP message in mutant embryos while the bulk of the mRNA was predicted to encode the altered proteins indicated in Figure 1D .
The structure of the mutant mRNAs predicted that two species of altered protein would each make up about half of the total protein: an amino-terminal fragment of about 385 amino acids and a full length protein with a three amino acid insert at amino acid 372 ( Figure 1C ). To examine this prediction we performed western blot analysis of embryo extracts using an amino-terminal FRAP antibody (Fig.   1E ). The predicted amino-terminal fragment was not detectable suggesting that it was unstable or insoluble. The levels of the full-length form of FRAP were reduced to approximately one half the level present in wild-type animals, consistent with the predictions of the mRNA analysis.
After confirming the mutation in the FRAP gene we examined the activity of the FRAP signaling pathway in the flat-top mutants. We assayed the ability of FRAP immunoprecipitated from flat-top embryos to phosphorylate the S6 kinase p70 s6k in vitro. Kinase activity of FRAP on this substrate is significantly reduced by the flat-top mutation (Fig 2A) . The extent of this defect on the overall phosphorylation level of p70 s6k in vivo was assessed by western blotting (Fig 2B) . p70 s6k from flat-top embryos co-migrates on SDS PAGE with the hypo-phosphorylated form of p70 s6k found in rapamycintreated HEK293 cells, in contrast to the hyper-phosphorylated state of the enzyme in wild-type embryos (Fig 2B) . The phosphorylation of a specific residue, Thr 389, is sensitive to rapamycin in vivo 8 . Western blotting using a phospho-specific antibody revealed a dramatic reduction in the phosphorylation of Thr 389 in flat-top embryos, similar to the results seen in rapamycin treated cells (Fig 2B) . Since phosphorylation of Thr 389 is thought to be an important means of regulating of p70 s6k kinase activity 23 ,
we assayed the ability of p70 s6k to phosphorylate a peptide substrate derived from the S6 ribosomal subunit in vitro. This revealed that p70 s6k activity in flat-top embryos is reduced to 17% of the level in wild-type embryos ( Table 1) .
The reduction in FRAP activity could be the result of a 50% in the levels of 'full length' protein product or might also reflect reduced activity of the altered proteins encoded by mRNAs C and B.
Activity against p70 s6k is reduced more than the predicted 50%, suggesting that the altered proteins have reduced activity. To examine this we produced plasmids that express each of the flat-top mRNAs separately (wt, mRNA B and mRNA C, see figure 1 C and D). A FLAG epitope and a mutation conferring rapamycin resistance were added to allow FRAP activity to be measured in transfected cells against the background of endogenous FRAP. The activity of the mutant proteins was assessed against a second major target of FRAP kinase activity, 4E-BP1 (Fig. 3) . HEK293 cells were co-transfected with an individual FRAP expression plasmid and with an HA-tagged 4E-BP1 construct. Each combination was assessed in the presence or absence of rapamycin. 4E-BP1 was immunoprecipitated from the cells, and phosphorylation of Ser65 and Thr70, residues shown to be FRAP targets, were analyzed by Western blot with an anti-phospho Ser65 antibody ( Fig 3A) and anti-phospho Thr70 antibody (Fig 3B) . The results show that HEK293 cells transfected with the wild-type FRAP protein efficiently phosphorylate 4E-BP1 at Ser65 and Thr70. In contrast, both the protein containing a three amino acid insertion (mRNA B) and that with a three amino acid deletion (mRNA C) have drastically reduced activity, similar to that produced by a mutation in the active site of the kinase (kinase dead in Fig 3. ) These results demonstrate that the altered proteins produced by the flat-top allele of FRAP have drastically reduced activity, despite the fact that the lesions are far from the active site.
We next examined the developmental expression pattern of FRAP, p70 s6k
, and 4E-BP1 to determine if the genes were expressed in tissues that are abnormal in the flat-top embryo. At 8.5 dpc prominent FRAP mRNA expression in the mid-thoracic region of the embryo is apparent (Fig 4A) . Expression spreads quickly and is quite widespread by 9.5 dpc (Fig 4B) . Some regional variation in expression was apparent, for example expression is higher in the neuroectoderm, higher yet in rhombomeres 3 and 5 and absent or at low levels in the heart. This widespread pattern suggested that the expression of downstream targets might be a more important determinant of the specific defects seen in flat-top mice.
We also examined the expression pattern of 4E-BP1 and p70 s6k in wild-type embryos. The expression patterns of p70 s6k and 4E-BP1 are more restricted, consistent with the onset of developmental defects in flat-top embryos. High levels of expression are found in the neuroectoderm of the developing telencephalon and the surrounding mesenchyme (shown for 4E-BP1 in Fig 4) . The highest levels of 4E-BP1 expression at 8.5 dpc are also in the presumptive telencephalon, suggesting that defects in 4E-BP1 and p70 s6k activity result in the specific proliferation defects in the telencephalic neuroectoderm of flat-top mutants.
Our previous analysis of the flat-top phenotype showed that the telencephalic defect was due to a failure to up-regulate the rate of proliferation in the neuroectoderm 22 . In Drosophila, both FRAP and S6 kinase activities are necessary to maintain a consistent cell size during development and a 50% reduction in S6 kinase activity has a discernible effect [15] [16] . Mice have two S6 kinase genes and the activity of both is strongly inhibited by rapamycin 17 . Thus it seemed possible that an effect on cell size might also play a role in the developmental defects in flat-top mice. We examined the size of cells in flat-top mice by two different means. The size of dissociated cells from whole, mutant or unaffected littermate controls was compared using forward light scatter in a fluorescence activated cell sorter.
This analysis revealed the same distribution of cell sizes in mutant and wild-type embryos but approximately 1/3rd fewer cells in mutant embryos. To examine cell size in a more direct fashion, we recovered mesenchymal cells from the mid-thoracic region of embryos, the earliest site of FRAP expression, and measured cell diameters (Fig. 5 ). This analysis did not detect an effect of the mutation on cell size.
Since reduced FRAP kinase activity causes abnormal development in flat-top embryos, we examined whether rapamycin treatment of normal embryos could cause similar defects in embryonic development. We injected wild-type pregnant mice with a dose regimen of rapamycin comparable to the therapeutic dose given to humans, and analyzed the embryos at 9.5 dpc. 100% of embryos (n=33) from these females phenocopied the flat-top homozygous mutant embryo ( Figure 6B ). Western blot analysis with p70 s6k Thr398 phospho-specific antibody demonstrated that phosphorylation of p70 s6k is reduced in rapamycin treated embryos (data not shown), consistent with the idea that the effects of rapamycin on embryogenesis were due to the known targets of FRAP. These results provide further evidence that the FRAP mutation is the cause of abnormal development in the flat-top mutant embryo.
Discussion
We present for the first time a mouse with a mutation in the FRAP gene. The flat-top mouse mutant has many patterning defects, especially in the developing telencephalon, demonstrating that FRAP activity is necessary for proper embryonic forebrain development. The targets of the FRAP kinase, p70 s6k and 4E-BP1 are not phosphorylated in the flat-top mutants, demonstrating that the mutation affects FRAP kinase activity. Although the flat-top mutant allele of FRAP has a three amino acid insertion into a region of the FRAP protein that has not been previously characterized to perform a specific function, our analysis of the flat-top FRAP allele in transfection assays demonstrates that this mutation blocks FRAP kinase activity towards 4E-BP1.
The mouse FRAP mutation does not affect cell size. This is an interesting difference from the described Drosophila FRAP mutants [15] [16] and the mouse and Drosophila p70 s6k mutants 17, 14 . We propose that while in Drosophila FRAP regulates cell growth, in the mouse this function is controlled by downstream targets of FRAP, such as p70 s6k
. However, in the flat-top mutant cell proliferation is abnormal, suggesting that in the mouse FRAP does integrate mitogenic signals to up-regulate cell proliferation in development. Tissues that require a rapid increase in cell proliferation, such as the telencephalon, ventral body walls, and limb buds, are all abnormal in flat-top mutants 22 . FRAP activity may also be required for a shortening of the G 1 phase of the cell cycle during embryonic development, thus allowing more rapid cell proliferation in certain embryonic regions. The embryo does not have a G 1 phase of the cell cycle until after gastrulation, indicating that FRAP activity does not function in the regulation of development until after gastrulation.
The rapamycin induced phenocopy of the flat-top mutant provides strong evidence that the mutation in FRAP is causative of the flat-top phenotype. There are no other known rapamycin sensitive genes in the flat-top critical region determined by meiotic mapping of the mutation, and characterization of the region from the human genome sequencing project has not identified any other genes in the region involved in the FRAP sequencing pathway. The phenocopy of the flat-top mutation by injection of rapamycin into wild-type pregnant mice also demonstrates that rapamycin is a teratogen. As its use increases as an immunosuppressant and a possible anti-cancer agent, its teratogenic potential should be considered.
Further studies are necessary to determine the mechanism of the flat-top mutation. However, new studies on FRAP signaling show that FRAP must shuttle between the nucleus and cytoplasm to have signaling activity 23 . We can speculate that perhaps the flat-top FRAP allele with the three amino acid insertion disrupts the ability of FRAP either to enter or to leave the nucleus. It has also been demonstrated that FRAP kinase activity is required for the expression of cyclin D1 protein in pancreatic cancer cells 11 . It is possible that the flat-top FRAP mutation blocks the translation of cyclin D1 in the developing embryo, resulting in a loss of cell proliferation in the telencephalon and other areas affected by the flattop mutation. Further study of the flat-top mutant will validate in vitro results regarding the FRAP signaling pathway, and will seek to determine the role of FRAP activity in embryonic development and cell proliferation. Table 1 p70 s6 Kinase activity. The ability of p70 S6k to phosphorylate S6 was assessed in extracts from flat-top mutants, wild-type embryos, and HEK293 cells was analyzed as described (16) . No activity was seen in samples that were not incubated with antibody for immunoprecipitation (293, no Ab). The result of a representative experiment are shown. The experiment was repeated 4 times with similar results. Fig. 2 The expression domain has expanded from that seen at 8.5dpc. However, there appears to be little or no FRAP expression in the heart. Also, hindbrain rhombomeres 3 and 5 have higher levels of FRAP expression than surrounding tissues. (B) 4E-BP1 expression at 8.5 dpc. The expression is relatively low overall with the highest level of expression in the ventral portion of the forebrain and the surrounding mesenchyme. (E) Overall 4E-BP1 expression at 9.5 dpc. A section through the head (C) shows high levels of expression in the ventral telencephalic neurectoderm and surrounding mesenchyme but not in the surface ectoderm. A single cell suspension was generated from the mid-thoracic region of either wild-type or flat-top mutant embryos at 9.5dpc and cells were measured to determine size. There is no significant difference between flat-top (left) and wild-type (right) cell diameters.
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